UCL School of Pharmacy


Interreg 2 Seas 2 Mers

Interreg project logos

The IMODE project is dedicated to address the unmet challenges of biopharmaceutical/biomedical field by exploration and development of novel techniques and therapeutic medicines for improvement in the sector of healthcare society in cost effective manner.

IMODE is funded by the European Interreg 2 Seas programme and cofinanced by the European Fund for Regional Development (ERFD).

The collaboration of academic research groups through a various disciplines applied research programme in materials science, pharmacy, biology and medicine will aid in the achieving the aforementioned aim.

Contact Person:

Professor Duncan Craig
Director, UCL School of Pharmacy
Novel Pharmaceutical development unit
Project Manager
Tel: +44 (0)20 7753 5819
Email: duncan.craig@ucl.ac.uk

Contact Person:

Project aim:

Development of innovative pharmaceutical formulation and technologies.


The purpose of the project is to enhance the R&D on major healthcare challenges for superior healthcare by design and fabrication of novel pharmaceutical products through development of new multicomponent drug delivery systems.

  • Identification of novel GRAS status composite materials.

Identification of novel Generally Recognized as Safe (GRAS) status composite materials with enhanced spinning and mechanical properties for further processing to act as matrices for the multicomponent drug system.

  • Physicochemical characterization of nanoformulations.

Development of novel physical characterization, drug release, dissolution studies and modeling approaches which will allow prediction of product structure and stability, essential for commercial development.

  • Product development for advanced drug delivery.

Formulation of novel system and in vitro assessment of the dosage form.

Imode project budget information

Budget: 5 910 275
Head of Project: University of Lille – Sciences and Technologies – FR
Project partners:
University College of London (UK), University of Lille – Faculty of medicine (FR), University of East Anglia (UK), University of Greenwich (UK), Ashford and St. Peter’s Hospitals NHS Foundation Trust (UK), Cubic Pharmaceutical Ltd (UK), University of Ghent (BE)ImaBiotech (FR), Roquette Frères (FR), Eurasante (FR).

Activities carried out by UCL:

•    Development of novel GRAS status composite nanomaterials
•    Nanofabrication of composite material by development of fabrication technique.
•    Communication activities, building network and organizing events.

Expected outcomes:

  • Development of innovative tech. for material formulation (TRL4).
  • Development of both high throughput and high value manufacturing technique (nanofibrous and nanocomposite matrix approaches) which allow commercially feasible production.

    Germ bacteria

Duration: 48 months
Official start: 01.07.2016
Find out more: https://www.interreg2seas.eu/en/imode